Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Outstanding (2016 - 2025)

Syndax Pharmaceuticals has reported Shares Outstanding over the past 11 years, most recently at $87.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $87.4 million for Q4 2025, up 2.0% from a year ago — trailing twelve months through Dec 2025 was $87.4 million (up 2.0% YoY), and the annual figure for FY2025 was $87.4 million, up 2.0%.
  • Shares Outstanding for Q4 2025 was $87.4 million at Syndax Pharmaceuticals, up from $86.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding for SNDX hit a ceiling of $87.4 million in Q4 2025 and a floor of $48.2 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $69.5 million (2023), compared with a mean of $71.0 million.
  • Biggest five-year swings in Shares Outstanding: soared 59.55% in 2021 and later rose 1.02% in 2024.
  • Syndax Pharmaceuticals' Shares Outstanding stood at $55.0 million in 2021, then rose by 23.88% to $68.1 million in 2022, then rose by 24.54% to $84.8 million in 2023, then grew by 1.02% to $85.7 million in 2024, then grew by 2.0% to $87.4 million in 2025.
  • The last three reported values for Shares Outstanding were $87.4 million (Q4 2025), $86.9 million (Q3 2025), and $86.1 million (Q2 2025) per Business Quant data.